Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STAND: Transitioning from Alendronate to Denosumab in Postmenopausal Osteoporosis
NCT00377819Phase 3Completed
- Sponsor
- Amgen
- Start
- Sep 2006
- Primary completion
- Mar 2008
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
01
Overview
Phase 3, randomised, double-blind trial of denosumab in postmenopausal osteoporosis (2 arms), sponsored by Amgen. Primary endpoint: Percent Change From Baseline in Total Hip Bone Mineral Density at 12 months. Started Sep 2006; status: completed.
02
Drugs
denosumab
03
Conditions
postmenopausal osteoporosis
Beyond the preview
Go deeper on NCT00377819.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00377819.